

GenMark Diagnostics, Inc.  
Form 10-Q  
May 03, 2016  
Table of Contents

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

FORM 10-Q

(Mark One)

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2016

or

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from \_\_\_\_\_ to \_\_\_\_\_

Commission File Number: 001-34753

GenMark Diagnostics, Inc.  
(Exact name of registrant as specified in its charter)

Delaware 27-2053069  
(State or other jurisdiction of (I.R.S. Employer  
incorporation or organization) Identification No.)

5964 La Place Court 92008-8829  
Carlsbad, California  
(Address of principal executive offices) (Zip code)

Registrant's telephone number, including area code: 760-448-4300

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports) and (2) has been subject to such filing requirements for the past 90 days. Yes  No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes  No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See definitions of "large accelerated filer," "accelerated filer" and "smaller reporting company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer  Accelerated filer

Non-accelerated filer  Smaller reporting company

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes  No

The number of outstanding shares of the registrant's common stock on April 29, 2016, was 42,788,585.

Table of Contents

GENMARK DIAGNOSTICS, INC.  
TABLE OF CONTENTS

	Page
PART I. FINANCIAL INFORMATION	
Item 1. <u>Financial Statements</u>	<u>3</u>
Item 2. <u>Management's Discussion and Analysis of Financial Condition and Results of Operations</u>	<u>16</u>
Item 3. <u>Quantitative and Qualitative Disclosures About Market Risk</u>	<u>22</u>
Item 4. <u>Controls and Procedures</u>	<u>22</u>
PART II. OTHER INFORMATION	
Item 1. <u>Legal Proceedings</u>	<u>23</u>
Item 1A. <u>Risk Factors</u>	<u>23</u>
Item 2. <u>Unregistered Sales of Equity Securities and Use of Proceeds</u>	<u>23</u>
Item 3. <u>Defaults Upon Senior Securities</u>	<u>23</u>
Item 4. <u>Mine Safety Disclosures</u>	<u>23</u>
Item 5. <u>Other Information</u>	<u>23</u>
Item 6. <u>Exhibits</u>	<u>23</u>

Table of Contents

## PART I. FINANCIAL INFORMATION

## ITEM 1. FINANCIAL STATEMENTS

## GENMARK DIAGNOSTICS, INC.

## UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS

(In thousands, except par value)

	March 31, 2016	December 31, 2015
Current assets		
Cash and cash equivalents	\$ 27,913	\$ 35,385
Marketable securities	10,075	10,080
Accounts receivable, net of allowances of \$2,756 and \$2,727, respectively	5,433	6,847
Inventories	2,441	3,054
Prepaid expenses and other current assets	623	591
Total current assets	46,485	55,957
Property and equipment, net	11,705	11,396
Intangible assets, net	2,282	2,376
Restricted cash	758	758
Other long-term assets	178	180
Total assets	\$ 61,408	\$ 70,667
Current liabilities		
Accounts payable	\$ 5,130	\$ 4,376
Accrued compensation	4,489	3,861
Other current liabilities	1,907	2,352
Total current liabilities	11,526	10,589
Long-term liabilities		
Deferred rent	1,281	1,257
Long-term debt	9,562	9,890
Other non-current liabilities	319	334
Total liabilities	22,688	22,070
Stockholders' equity		
Preferred stock, \$0.0001 par value; 5,000 authorized, none issued	—	—
Common stock, \$0.0001 par value; 100,000 authorized; 42,788 and 42,551 shares issued and outstanding as of March 31, 2016 and December 31, 2015, respectively	4	4
Additional paid-in capital	356,344	353,233
Accumulated deficit	(317,627)	(304,669)
Accumulated other comprehensive income (loss)	(1)	29
Total stockholders' equity	38,720	48,597
Total liabilities and stockholders' equity	\$ 61,408	\$ 70,667

See accompanying notes to unaudited condensed consolidated financial statements.

## GENMARK DIAGNOSTICS, INC.

## UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS

(In thousands, except per share data)

	Three Months Ended March 31,	
	2016	2015
Revenue		
Product revenue	\$ 10,959	\$ 10,012
License and other revenue	105	95
Total revenue	11,064	10,107
Cost of revenue	4,375	3,991
Gross profit	6,689	6,116
Operating expenses		
Sales and marketing	3,709	3,693
General and administrative	3,419	3,671
Research and development	12,269	8,779
Total operating expenses	19,397	16,143
Loss from operations	(12,708)	(10,027)
Other income (expense)		
Interest income	29	36
Interest expense	(277 )	(73 )
Other income	33	217
Total other income (expense)	(215)	180
Loss before provision for income taxes	(12,923)	(9,847)
Income tax expense	35	22
Net loss	\$(12,958)	\$(9,869 )
Net loss per share, basic and diluted	\$(0.30 )	\$(0.24 )
Weighted average number of shares outstanding, basic and diluted	42,672	41,774
Other comprehensive loss		
Net loss	\$(12,958)	\$(9,869 )
Foreign currency translation adjustments	47	9
Net unrealized losses on marketable securities, net of tax	(17 )	(17 )
Comprehensive loss	\$(12,928)	\$(9,877 )

See accompanying notes to unaudited condensed consolidated financial statements.

Table of Contents

## GENMARK DIAGNOSTICS, INC.

## UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(In thousands)

	Three Months Ended March 31,	
	2016	2015
Operating activities		
Net loss	\$(12,958)	\$(9,869)
Adjustments to reconcile net loss to net cash used in operating activities:		
Depreciation and amortization	900	797
Amortization of premiums on investments	16	73
Amortization of deferred debt issuance costs	92	49
Gain on sale of investment in preferred stock	—	(223)
Stock-based compensation	2,402	2,339
Provision for bad debt	29	—
Non-cash inventory adjustments	75	402
Other non-cash adjustments	(49)	) 20
Changes in operating assets and liabilities:		
Accounts receivable	1,385	445
Inventories	501	(366)
Prepaid expenses and other assets	—	(216)
Accounts payable	617	(775)
Accrued compensation	989	(919)
Other liabilities	(42)	) (22)
Net cash used in operating activities	(6,043)	) (8,265)
Investing activities		
Payments for intellectual property licenses	(800)	) (550)
Purchases of property and equipment	(966)	) (411)
Purchases of marketable securities	—	(14,797)
Proceeds from sales of marketable securities	—	223
Maturities of marketable securities	—	14,350
Net cash used in investing activities	(1,766)	) (1,185)
Financing activities		
Principal repayment of borrowings	(5)	) (5)
Proceeds from borrowings	—	10,000
Costs associated with debt issuance	(10)	) (700)
Proceeds from stock option exercises	345	222
Net cash provided by financing activities	330	9,517
Effect of exchange rate changes on cash	7	(9)
Net increase (decrease) in cash and cash equivalents	(7,472)	) 58
Cash and cash equivalents at beginning of period	35,385	36,855
Cash and cash equivalents at end of period	\$27,913	\$36,913
Non-cash investing and financing activities		
Transfer of instruments from property and equipment to inventory	\$38	\$48
Property and equipment costs included in accounts payable	\$285	\$818
Supplemental cash flow disclosures		
Cash paid for income taxes, net	\$13	\$17
Cash received for interest	\$21	\$109

Cash paid for interest	\$184	\$73
------------------------	-------	------

See accompanying notes to unaudited condensed consolidated financial statements.

Table of Contents

GENMARK DIAGNOSTICS, INC.

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

1. Organization and Basis of Presentation

GenMark Diagnostics, Inc., the Company or GenMark, was formed by Osmetech plc as a Delaware corporation in February 2010, and had no operations prior to its initial public offering, which was completed in June 2010. The Company is a leading provider of automated, multiplex molecular diagnostic testing systems that detect and measure DNA and RNA targets to diagnose disease and optimize patient treatment.

Basis of Presentation

The Company has incurred net losses from operations since its inception and had an accumulated deficit of \$317,627,000 as of March 31, 2016. Management expects operating losses to continue for the foreseeable future. The Company's ability to transition to profitable operations is dependent upon achieving a level of revenues adequate to support its cost structure through expanding its product offerings and consequently increasing its product revenues. Cash, cash equivalents and marketable securities as of March 31, 2016 were \$37,988,000. The Company has prepared cash flow forecasts which indicate, based on the Company's current cash resources available, that the Company will have sufficient resources to fund its business for at least the next 12 months.

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with United States generally accepted accounting principles, or U.S. GAAP, and applicable regulations of the U.S. Securities and Exchange Commission, or the SEC, and should be read in conjunction with the audited financial statements included in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2015 filed with the SEC on February 23, 2016. These unaudited condensed consolidated financial statements reflect all adjustments that are, in the opinion of management, necessary for a fair statement of the results for the interim periods presented. These adjustments are of a normal, recurring nature. Interim period operating results may not be indicative of the operating results for the full year or any future period.

Principles of Consolidation

The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation.

Use of Estimates

The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and the notes thereto. The Company's significant estimates included in the preparation of the financial statements are related to accounts receivable, inventories, property and equipment, intangible assets, employee-related compensation accruals, warranty liabilities, tax valuation accounts and stock-based compensation. Actual results could differ from those estimates.

Segment Information

The Company currently operates in one reportable business segment, which encompasses the development, manufacturing, sales and support of instruments and molecular tests based on its proprietary eSensor® detection technology. Substantially all of the Company's operations and assets are in the United States of America.

Recent Accounting Pronouncements

From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board, or the FASB, or other standard setting bodies that the Company adopts as of the specified effective date. The Company believes that the impact of recently issued standards that are not yet effective will not have a material impact on its financial condition or results of operations upon adoption.

In February 2016, the FASB issued Accounting Standards Update, or ASU, No. 2016-02, Leases. This ASU requires lessees to recognize the assets and liabilities on their balance sheet for the rights and obligations created by most leases and continue to recognize expenses on their income statements over the lease term. It will also require disclosures designed to give financial statement users information on the amount, timing, and uncertainty of cash flows arising from leases. The guidance is effective for annual reporting periods beginning after December 15, 2018, and interim periods within those years. Early adoption is permitted for all entities. The Company is currently evaluating the impact of ASU 2016-02 on its consolidated financial statements and disclosures.

In November 2015, the FASB issued ASU No. 2015-17, Balance Sheet Classification of Deferred Taxes, an update to ASC 740, Income Taxes. Current U.S. GAAP requires an entity to separate deferred income tax liabilities and assets into current

## Table of Contents

and noncurrent amounts in a classified statement of financial position. To simplify the presentation of deferred income taxes, the amendments in ASU 2015-17 require that deferred tax liabilities and assets be classified as noncurrent in a classified statement of financial position. The current requirement that deferred tax liabilities and assets of a tax-paying component of an entity be offset and presented as a single amount is not affected by the amendments in ASU 2015-17. The Company adopted ASU 2015-17 as of the fiscal year ended December 31, 2015 and the interim period ending March 31, 2016 on a prospective basis.

In August 2015, the FASB issued ASU 2015-14, Revenue from Contracts with Customers, which has deferred the implementation of the previously issued ASU 2014-09. This standard is based on the principle that revenue should be recognized to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. ASU 2014-09 will be effective for the Company beginning in the first fiscal quarter of 2018 and allows for a full retrospective or a modified retrospective adoption approach. The new standard does not have a current impact on the unaudited consolidated financial statements presented. The Company is currently evaluating the impact of ASU 2014-09 on its consolidated financial statements.

### Cash, Cash Equivalents and Marketable Securities

Cash and cash equivalents consist of cash on deposit with banks, money market instruments and certificates of deposit with original maturities of three months or less at the date of purchase. Marketable securities consist of certificates of deposits that mature in greater than three months. Marketable securities are accounted for as "available-for-sale" with the carrying amounts reported in the balance sheets stated at cost, which approximates their fair market value, with unrealized gains and losses, if any, reported as a separate component of stockholders' equity and included in comprehensive loss.

### Restricted Cash

Restricted cash represents amounts designated for uses other than current operations and included \$758,000 as of March 31, 2016, held as security for the Company's letter of credit with Banc of California.

### Receivables

Accounts receivable consist of amounts due to the Company for sales to customers and are recorded net of an allowance for doubtful accounts. The allowance for doubtful accounts is determined based on an assessment of the collectability of specific customer accounts, the aging of accounts receivable, and a reserve for unknown items based upon the Company's historical experience.

### Product Warranties

The Company generally offers a one-year warranty for its instruments sold to customers and typically up to a 60 day warranty for consumables. Factors that affect the Company's warranty reserves include the number of units sold, historical and anticipated rates of warranty repairs, and the cost per repair. The Company periodically assesses the adequacy of its warranty reserve and adjusts the amount as appropriate.

### Intangible Assets

Intangible assets are comprised of licenses or sublicenses to technology covered by patents owned by third parties, and are amortized on a straight-line basis over the expected useful lives of these assets, which is generally 10 years. Amortization of licenses typically begins upon the Company obtaining access to the licensed technology and is recorded in cost of revenues for licenses supporting commercialized products. The amortization of licenses to technology supporting products in development is recorded in research and development expenses.

### Impairment of Long-Lived Assets

The Company assesses the recoverability of long-lived assets, including intangible assets, by periodically evaluating the carrying value whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. If impairment is indicated, the Company writes down the carrying value of the asset to its estimated fair value. This fair value is primarily determined based on estimated discounted cash flows.

#### Inventories

Inventories are stated at the lower of cost (first-in, first-out) or net realizable value and include direct labor, materials, and manufacturing overhead. The Company periodically reviews inventory for evidence of slow-moving or obsolete parts, and writes inventory down to net realizable value, as needed. This write down is based on management's review of inventories on hand, compared to estimated future usage and sales, shelf-life assumptions, and assumptions about the likelihood of obsolescence. If actual market conditions are less favorable than those projected by the Company, additional inventory write-downs may be required. Inventory impairment charges establish a new cost basis for inventory and charges are not reversed subsequently to income, even if circumstances later suggest that increased carrying amounts are recoverable.

Table of Contents

## Property and Equipment, net

Property, equipment and leasehold improvements are recorded at cost and depreciated using the straight-line method over the estimated useful lives of the assets, which are identified below. Repair and maintenance costs are expensed as incurred.

Machinery and laboratory equipment	3 - 5 years
Instruments	4 - 5 years
Office equipment	5 years
Leasehold improvements	over the shorter of the remaining life of the lease or the useful economic life of the asset

## Income Taxes

Current income tax expense is the amount of income taxes expected to be payable for the current year. A deferred income tax liability or asset is established for the expected future tax consequences resulting from the differences in financial reporting and tax bases of assets and liabilities. A valuation allowance is provided if it is more likely than not that some or all of the deferred tax assets will not be realized. A full valuation allowance has been recorded against the Company's net deferred tax assets due to the uncertainty surrounding the Company's ability to utilize these assets in the future. The Company provides for uncertain tax positions when such tax positions do not meet the recognition thresholds or measurement standards prescribed by the authoritative guidance on income taxes. Amounts for uncertain tax positions are adjusted in periods when new information becomes available or when positions are effectively settled. The Company recognizes accrued interest related to uncertain tax positions as a component of income tax expense.

A tax position that is more likely than not to be realized is measured at the largest amount of tax benefit that is greater than 50% likely of being realized upon settlement with the taxing authority that has full knowledge of all relevant information. Measurement of a tax position that meets the more likely than not threshold considers the amounts and probabilities of the outcomes that could be realized upon settlement using the facts, circumstances and information available at the reporting date.

## 2. Stock-Based Compensation

The Company recognizes stock-based compensation expense related to stock options, restricted stock awards, restricted stock units, and market-based stock units granted to employees and directors in exchange for services under the Company's 2010 Equity Incentive Plan, or the 2010 Plan, and employee stock purchases under the Company's 2013 Employee Stock Purchase Plan, or the ESPP. Employee participation in the 2010 Plan is at the discretion of the Compensation Committee of the Board of Directors of the Company. Each equity award grant reduces the number of shares available for grant under the 2010 Plan. Stock-based compensation expense is based on the fair value of the applicable award utilizing various assumptions regarding the underlying attributes of the applicable award. The estimated fair value, net of forfeitures expected to occur during the vesting period, is amortized as compensation expense on a straight-line basis to reflect vesting as it occurs. Stock-based compensation expense is recorded in cost of sales, sales and marketing, research and development, and/or general and administrative expenses based on the employee's respective function. During the three months ended March 31, 2016 and 2015, aggregate stock-based compensation expense was \$2,402,000 and \$2,339,000, respectively.

The fair value of stock options granted is derived from the Black-Scholes Option Pricing Model, which uses several judgment-based variables to calculate the expense. The inputs include the expected term of the stock option, the expected volatility and other factors.

- **Expected Term.** Expected term represents the period that the stock-based awards are expected to be outstanding and is determined by using the simplified method.

- **Expected Volatility.** Expected volatility represents the estimated volatility in the Company's stock price over the expected term of the stock option and is determined by review of the Company's and similar companies' historical experience.
- **Expected Dividend.** The Black-Scholes Option Pricing Model calls for a single expected dividend yield as an input. The Company has assumed no dividends as it has never paid dividends and has no current plans to do so.
- **Risk-Free Interest Rate.** The risk-free interest rate used in the Black-Scholes Option Pricing Model is based on published U.S. Treasury rates in effect at the time of grant for periods corresponding with the expected term of the option.

All stock options granted under the 2010 Plan are exercisable at a per share price equal to the closing quoted market price of a share of the Company's common stock on the NASDAQ Global Market on the grant date and generally vest over a

Table of Contents

period of between one and four years. Stock options are generally exercisable for a period of up to 10 years after grant and are typically forfeited if employment is terminated before the options vest.

The following table summarizes stock option activity during the three months ended March 31, 2016:

	Number of Shares	Weighted Average Exercise Price
Outstanding at December 31, 2015	3,004,011	\$ 9.74
Granted	5,000	4.70
Exercised	(55,352)	6.24
Cancelled	(78,439)	10.59
Outstanding at March 31, 2016	2,875,220	9.78
Vested and expected to vest at March 31, 2016	2,741,406	9.67
Exercisable at March 31, 2016	1,744,344	\$ 8.42

The weighted average fair value of stock options granted during the three months ended March 31, 2016 was \$2.27. Options that were exercisable as of March 31, 2016 had a remaining weighted average contractual term of 6.14 years, and an aggregate intrinsic value of \$473,000. As of March 31, 2016, there were 2,875,220 stock options outstanding, which had a remaining weighted average contractual term of 7.06 years and an aggregate intrinsic value of \$476,000.

The following table presents the weighted average assumptions used by the Company to estimate the fair value of stock options granted, as well as the resulting weighted average fair values for the three months ended March 31, 2016:

	Three Months Ended March 31, 2016		2015	
Expected volatility	51 %	50 %		
Expected life (years)	5.90	6.08		
Risk-free interest rate	1.35%	1.69%		
Expected dividend	— %	— %		
Weighted average fair value	\$2.27	\$6.44		

Restricted stock awards or units may be granted in connection with the hiring or retention of personnel and are subject to certain conditions. In March 2013, the Company transitioned to granting restricted stock units under the 2010 Plan in lieu of granting restricted stock awards. The compensation expense related to the restricted stock awards or units is calculated as the fair market value of the stock on the grant date and is adjusted for estimated forfeitures. The Company's restricted stock award and restricted stock unit activity for the three months ended March 31, 2016 was as follows:

	Restricted Stock Awards		Restricted Stock Units	
	Number of Shares	Weighted Average Grant Date Fair Value	Number of Shares	Weighted Average Grant Date Fair Value
Unvested at December 31, 2015	32,837	\$ 5.00	934,977	\$ 12.66
Granted	—	—	1,229,342	4.70
Vested	(24,692)	4.44	(176,342)	12.76

Edgar Filing: GenMark Diagnostics, Inc. - Form 10-Q

Cancelled	—	—	(26,659)	9.28
Unvested at March 31, 2016	8,145	\$ 6.68	1,961,318	\$ 7.33

9

---

Table of Contents

As of March 31, 2016, there was \$37,000 of unrecognized compensation cost related to unvested restricted stock awards, which is expected to be recognized over a weighted average period of 0.39 years. The total fair value of restricted stock awards that vested during the three months ended March 31, 2016 and 2015 was \$110,000 and \$561,000, respectively.

As of March 31, 2016, there was \$10,105,000 of unrecognized compensation cost related to unvested restricted stock units, which is expected to be recognized over a weighted average period of 2.93 years. The total fair value of restricted stock units that vested during the three months ended March 31, 2016 and 2015 was \$2,250,000 and \$2,708,000, respectively.

The Company issued market-based stock units in February 2015 and February 2016, which may result in the recipient receiving shares of stock equal to 200% of the target number of units granted. The vesting and issuance of Company stock depends on the Company's stock performance as compared to the NASDAQ Composite Index over a three-year period following the grant. As of March 31, 2016, there was \$1,493,000 of unrecognized stock-based compensation expense related to these awards, which is expected to be recognized over a weighted average period of 2.41 years. The Company's market-based stock unit activity for the three months ended March 31, 2016 was as follows:

	Market-Based Stock Units	Weighted Number of Shares	Average Grant Date Fair Value
Unvested at December 31, 2015	136,730	\$	18.07
Target units granted	263,351	4.94	
Vested	—	—	
Cancelled	—	—	
Unvested at March 31, 2016	400,081	\$	9.43

The fair value of these market-based stock units was estimated on the date of grant using the Monte Carlo Simulation Valuation Model, which estimates the potential outcome of achieving the market condition based on simulated future stock prices, with the following assumptions for the three months ended March 31, 2016:

	Three Months Ended March 31, 2016			
	2016	2015		
Expected volatility	49	%	45	%
Risk-free interest rate	0.90	%	1.10	%
Expected dividend	—	%	—	%
Weighted average fair value	\$4.94		\$18.07	

The Company issued 43,200 performance-based restricted stock units in March 2014 with a grant date fair value of \$12.30 per share. The vesting and issuance of Company stock pursuant to these awards depends on obtaining regulatory clearance of various products within a defined time. Stock-based compensation expense for performance-based awards is recognized when it is probable that the applicable performance criteria will be satisfied. The probability of achieving the relevant performance criteria is evaluated on a quarterly basis. As of March 31, 2016, there was \$266,000 of unrecognized stock-based compensation expense related to these awards.

## Employee Stock Purchase Plan

The Company's stockholders approved the ESPP in May 2013. A total of 650,000 shares of the Company's common stock were originally reserved for issuance under the ESPP, which permits eligible employees to purchase common stock at a discount through payroll deductions.

The price at which stock is purchased under the ESPP is equal to 85% of the fair market value of the Company's common stock on the first or the last day of the offering period, whichever is lower. Generally, each offering under the ESPP will be for a period of six months as determined by the Company's Board of Directors; provided that no offering period may exceed 27 months. Employees may invest up to 10% of their qualifying gross compensation through payroll deductions. In no event may an employee purchase more than 1,500 shares of common stock during any six-month offering period. As of March 31,

Table of Contents

2016, there were 405,897 shares of common stock available for issuance under the ESPP. The ESPP is a compensatory plan as defined by the authoritative guidance for stock compensation; therefore, stock-based compensation expense related to the ESPP has been recorded during the three months ended March 31, 2016.

### 3. Net Loss per Common Share

Basic net loss per share is calculated by dividing loss available to stockholders of the Company's common stock (the numerator) by the weighted average number of shares of the Company's common stock outstanding during the period (the denominator). Shares issued during the period and shares reacquired during the period are weighted for the portion of the period that they were outstanding. Diluted loss per share is calculated in a similar way to basic loss per share except that the denominator is increased to include the number of additional shares that would have been outstanding if the dilutive potential shares had been issued, unless the effect would be anti-dilutive.

The computations of diluted net loss per share for the three month periods ended March 31, 2016 and 2015 did not include the effects of the following stock options and other equity awards which were outstanding as of the end of each period because the inclusion of these securities would have been anti-dilutive (in thousands):

	Three Months Ended March 31, 2016 2015	
Options outstanding to purchase common stock	2,875	3,174
Other unvested equity awards	2,390	1,363
Total	5,265	4,537

### 4. Inventories

Inventory on hand as of March 31, 2016 and December 31, 2015 comprised the following (in thousands):

	March 31, December 31, 2016 2015	
Raw materials	\$ 982	\$ 1,147
Work-in-process	671	693
Finished goods	788	1,214
Total inventories	\$ 2,441	\$ 3,054

### 5. Property and Equipment, net

Property and equipment as of March 31, 2016 and December 31, 2015 comprised the following (in thousands):

	March 31, December 31, 2016 2015	
Property and equipment — at cost:		
Machinery and laboratory equipment	\$ 7,905	\$ 7,728
Instruments	9,097	8,195
Office equipment	1,562	1,526
Leasehold improvements	4,311	4,311
Total property and equipment — at cost	22,875	21,760
Less: accumulated depreciation	(11,170 )	(10,364 )
Property and equipment, net	\$ 11,705	\$ 11,396

Depreciation expense was \$806,000 and \$733,000 for the three months ended March 31, 2016 and 2015, respectively.



## 6. Intangible Assets, net

Intangible assets as of March 31, 2016 and December 31, 2015 comprised the following (in thousands):

	March 31, 2016			December 31, 2015		
	Gross Carrying Amount	Accumulated Amortization	Net Carrying Amount	Gross Carrying Amount	Accumulated Amortization	Net Carrying Amount
Intellectual property licenses	\$3,550	\$ (1,268 )	\$ 2,282	\$3,550	\$ (1,174 )	\$ 2,376

Intellectual property licenses have a weighted average remaining amortization period of 6.09 years as of March 31, 2016. Amortization expense for these licenses was \$94,000 and \$64,000 for the three months ended March 31, 2016 and 2015, respectively. Estimated future amortization expense for these licenses is as follows (in thousands):

Fiscal Years Ending	Future Amortization Expense
Remaining in 2016	\$ 281
2017	375
2018	375
2019	375
2020	375
Thereafter	501
Total	\$ 2,282

## 7. Loan Payable

As of March 31, 2016 and December 31, 2015, long-term debt consisted of the following (in thousands):

	March 31, December 31,	
	2016	2015
Term Loan A		
6.9% principal	\$ 10,000	\$ 10,000
Unamortized issuance premium	(421 )	(483 )
Total debt, net	9,579	9,517
Current portion of unamortized issuance premium	(17 )	373
Long-term debt	\$9,562	\$ 9,890

## Term Loans

In January 2015, the Company entered into a Loan and Security Agreement, or the LSA, with Solar Capital Partners (as successor-in-interest to General Electric Capital Corporation), and certain other financial institutions party thereto, as lenders, pursuant to which the Company obtained (a) up to \$35,000,000 in a series of term loans and (b) a revolving loan in the maximum amount of \$5,000,000. Under the terms of the LSA, the Company may, subject to certain conditions, borrow:

- \$10,000,000 on or before March 31, 2015, or Term Loan A;
- an additional \$10,000,000, or Term Loan B, subject to the Company's satisfaction of regulatory requirements necessary to CE Mark its ePlex system in Europe by a specified date; and
- an additional \$15,000,000, or Term Loan C, and together with Term Loan A and Term Loan B, the Term Loans, subject to the Company's satisfaction of FDA 510(k) market clearance for the sale of the Company's ePlex system in the United States by a specified date.

On March 27, 2015, the Company borrowed \$10,000,000 pursuant to Term Loan A. The Term Loans will accrue interest at a rate equal to, (a) the greater of 1.00% or the 3-year treasury rate in effect at the time of funding, plus (b) an applicable margin between 4.95% and 5.90% per annum. The Company is only required to make interest payments on amounts borrowed pursuant to the Term Loans from the applicable funding date until March 1, 2017, or the

Interest Only Period. Following the Interest Only Period, monthly installments of principal and interest under the Term Loans will be due until the original principal amount and applicable interest is fully repaid by January 12, 2019, or the Maturity Date.

Under the LSA, the Company is required to comply with certain affirmative and negative covenants, including, without limitation, delivering reports and notices relating to the Company's financial condition and certain regulatory events and intellectual property matters, as well as limiting the creation of liens, the incurrence of indebtedness, and the making of certain investments, payments and acquisitions, other than as specifically permitted by the LSA. As of March 31, 2016, the Company was in compliance with all covenants under the LSA.

On September 30, 2015, the Company entered into a first amendment to the LSA, pursuant to which the lenders internally reallocated certain funding commitments under the LSA between the lenders (but did not increase or reduce the aggregate amount of such commitments), and the parties adjusted certain of the Company's administrative financial reporting obligations and the dates by which certain future funding requirements must be satisfied. On March 18, 2016, the Company entered into a second amendment to the LSA, pursuant to which the parties adjusted the date by which the Company must satisfy the funding requirements in respect of Term Loan B.

#### Revolving Loan

Pursuant to the LSA, the Company may borrow up to \$5,000,000 under a revolving loan facility. Borrowings under the revolving loan will accrue interest at a rate equal to (a) the greater of 1.25% per annum or a base rate as determined by a three-month LIBOR-based formula, plus (b) an applicable margin between 2.95% and 3.95% based on certain criteria as set forth in the LSA. All principal and interest outstanding under the revolving loan is due and payable on the Maturity Date. Following the funding of Term Loan A, the Company is required to pay a commitment fee equal to 0.75% per annum of the amounts made available but unborrowed under the revolving loan. As of March 31, 2016, the Company had not borrowed any amounts pursuant the revolving loan facility.

#### Debt Issuance Costs

As of March 31, 2016 and December 31, 2015, the Company had \$421,000 and \$483,000, respectively, of unamortized debt issuance discount, which is offset against borrowings in long-term and short-term debt.

For the three months ended March 31, 2016 and 2015, amortization of debt issuance costs was \$92,000 and \$49,000, respectively. Amortization of debt issuance costs is included in interest expense in the Company's unaudited condensed consolidated statements of comprehensive loss for the periods presented.

#### Letter of Credit

In September 2012, the Company provided a \$758,000 letter of credit issued by Banc of California to the landlord of its executive office facility in Carlsbad, California. This letter of credit was secured with \$758,000 of restricted cash as of March 31, 2016.

Table of Contents

## 8. Leases

The Company has operating and capital lease agreements for its office, manufacturing, warehousing and laboratory space and for office equipment. Rent and operating expenses charged under these arrangements was \$387,000 and \$300,000 for the three months ended March 31, 2016 and 2015, respectively. Pursuant to the Company's lease agreements, a portion of the monthly rent has been deferred. The balance of deferred rent as of March 31, 2016 and December 31, 2015 was \$1,477,000 and \$1,445,000, respectively.

As of March 31, 2016, the future minimum lease payments required over the next five years under the Company's lease arrangements are as follows (in thousands):

Fiscal Years Ending	Future Minimum Lease Payments
Remaining in 2016	\$ 1,153
2017	1,632
2018	1,780
2019	1,907
2020	1,972
Thereafter	2,738
Total	\$ 11,182

## 9. Fair Value of Financial Instruments

The carrying amounts of financial instruments, such as cash equivalents, restricted cash, accounts receivable, and accounts payable approximate the related fair values due to the short-term maturities of these instruments.

The Company uses a fair value hierarchy with three levels of inputs, of which the first two are considered observable and the last unobservable, to measure fair value:

- Level 1 — Quoted prices in active markets for identical assets or liabilities.
- Level 2 — Inputs, other than Level 1, that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.
- Level 3 — Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.

The following table presents the financial instruments measured at fair value on a recurring basis and the valuation approach applied to each class of financial instruments as of March 31, 2016 and December 31, 2015 (in thousands):

	March 31, 2016			Total
	Quoted Prices in Active Markets for Identical Assets (Level 1)	Significant Other Observable Inputs (Level 2)	Significant Unobservable Inputs (Level 3)	
Money market funds (cash equivalents)	\$15,059	\$ —	\$ —	—\$15,059
Corporate notes and bonds	—	8,476	—	8,476
U.S. government and agency securities	—	800	—	800
Commercial paper	—	799	—	799

Edgar Filing: GenMark Diagnostics, Inc. - Form 10-Q

Total \$15,059 \$ 10,075 \$ — \$25,134

December 31, 2015

Quoted Prices

in  
Active Significant  
Markets Other Significant  
for Observable Unobservable  
Identical Inputs Total  
Assets (Level 2) (Level 3)  
(Level 1)

Money market funds (cash equivalents)	\$22,128	\$ —	\$	—\$22,128
Corporate notes and bonds	—	8,483	—	8,483
U.S. government and agency securities	—	799	—	799
Commercial paper	—	798	—	798
Total	\$22,128	\$ 10,080	\$	—\$32,208

Level 2 marketable securities are priced using quoted market prices for similar instruments or nonbinding market prices that are corroborated by observable market data. The Company uses inputs such as actual trade data, benchmark yields, broker/dealer quotes, and other similar data, which are obtained from quoted market prices, independent pricing vendors, or other sources, to determine the ultimate fair value of these assets and liabilities. The Company uses such pricing data as the primary input to make its assessments and determinations as to the ultimate valuation of its investment portfolio and has not made, during the periods presented, any material adjustments to such inputs.

## 10. Investments

The following table summarizes the Company's marketable securities as of March 31, 2016 and December 31, 2015 (in thousands):

	Amortized Cost	Gross Unrealized Gains	Gross Unrealized Losses	Estimated Fair Value
March 31, 2016				
Corporate notes and bonds	\$ 8,477	\$ —	\$ (1 )	\$ 8,476
U.S. government and agency securities	800	—	—	800
Commercial paper	799	—	—	799
Total	\$ 10,076	\$ —	\$ (1 )	\$ 10,075
December 31, 2015				
Corporate notes and bonds	\$ 8,495	\$ 1	\$ (13 )	\$ 8,483
U.S. government and agency securities	799	—	—	799
Commercial paper	798	—	—	798
Total	\$ 10,092	\$ 1	\$ (13 )	\$ 10,080

The following table summarizes the maturities of the Company's marketable securities as of March 31, 2016 (in thousands):

	Amortized Cost	Estimated Fair Value
Due in one year or less	\$ 10,076	\$ 10,075
Due after one year through two years	—	—
Total	\$ 10,076	\$ 10,075

## 11. Income Taxes

The Company uses an estimated annual effective tax rate, which is based on expected annual income, statutory tax rates and tax planning opportunities available in the various jurisdictions in which the Company operates, to determine its quarterly provision for income taxes. Certain significant or unusual items are separately recognized in the quarter in which they occur and can be a source of variability in the effective tax rates from quarter to quarter.

As of March 31, 2016, the Company recorded a full valuation allowance against all of its net deferred tax assets due to the uncertainty surrounding the Company's ability to utilize these assets in the future. Due to the Company's losses, it only records a tax provision or benefit related to uncertain tax positions and related interest and minimum tax payments or refunds. The Company recorded income tax expense of \$35,000 for the three months ended March 31, 2016.

The Company is subject to taxation in the United States and in various state and foreign jurisdictions. The Company's Federal and state returns since inception are subject to examination due to the carryover of net operating losses. As of March 31, 2016, the Company's tax years from 2011 through 2012 are subject to examination by the United Kingdom tax authorities related to legacy operations. The statute of limitations for the assessment and collection of income taxes related to other foreign tax returns varies by country. In the foreign countries where we have operations, these time periods generally range from three to five years after the year for which the tax return is due or the tax is assessed.



## ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

### Forward Looking Statements

The following discussion of our financial condition and results of operations should be read together with our unaudited condensed consolidated financial statements for the three months ended March 31, 2016 and the notes thereto included in Part I, Item 1 of this Quarterly Report, as well as the audited financial statements and notes thereto and Management's Discussion and Analysis of Financial Condition and Results of Operations included in our Annual Report on Form 10-K for the year ended December 31, 2015.

This Management's Discussion and Analysis of Financial Condition and Results of Operations contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, or the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act. These forward-looking statements regarding future events and our future results are based on current expectations, estimates, forecasts, and projections and the beliefs and assumptions of our management, including, without limitation, our expectations regarding our results of operations, sales and marketing expenses, general and administrative expenses, research and development expenses, and the sufficiency of our cash for future operations. Words such as "expect," "anticipate," "target," "project," "believe," "goals," "estimate," "potential," "pre," "may," "will," "might," "could," "intend," variations of these terms or the negative of those terms and similar expressions are intended to identify these forward-looking statements. Readers are cautioned that these forward-looking statements are subject to risks, uncertainties, and assumptions that are difficult to predict. Therefore, actual results may differ materially and adversely from those expressed in or implied by any forward-looking statements.

Among the important factors that could cause actual results to differ materially from those indicated by our forward-looking statements are those discussed under the heading "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2015 filed with the SEC on February 23, 2016. We assume no obligation to update these forward looking statements to reflect future events or circumstances.

### Trademarks and Trade Names

GenMark®, eSensor®, XT-8™ and ePlex™ and our other logos and trademarks are the property of GenMark Diagnostics, Inc. or its subsidiaries. All other brand names or trademarks appearing in this Quarterly Report are the property of their respective holders. Our use or display of other parties' trademarks, trade dress or products in this Quarterly Report does not imply that we have a relationship with, or the endorsement or sponsorship of, the trademark or trade dress owners.

### Overview

Our proprietary eSensor electrochemical technology enables fast, accurate and highly sensitive detection of multiple distinct biomarkers in a single sample. We are currently focused on developing and commercializing eSensor-based instruments and diagnostic tests for performing highly multiplexed reactions to simultaneously detect numerous, clinically relevant pathogens and/or genetic markers in rapidly expanding market segments. We currently sell our XT-8 instrument and related diagnostic and research tests, which collectively we refer to as our XT-8 system, in the United States. In addition, we have developed and intend to commercially launch our sample-to-answer ePlex instrument and its associated diagnostic tests, which we collectively refer to as our ePlex system, in Europe and the United States during 2016.

Our XT-8 system received 510(k) clearance from the United States Food and Drug Administration, or FDA, and is designed to support a broad range of molecular diagnostic and research tests with a compact and easy-to-use workstation and disposable test cartridges. Our XT-8 system supports up to 24 separate test cartridges, each of which can be run independently, resulting in a highly convenient and flexible workflow for our XT-8 customers, which are primarily hospitals and reference laboratories.

Since inception, we have incurred net losses from operations each year, and we expect to continue to incur losses for the foreseeable future. Our net losses for the three months ended March 31, 2016 and 2015 were approximately \$12,958,000 and \$9,869,000, respectively. As of March 31, 2016, we had an accumulated deficit of \$317,627,000. Our operations to date have been funded principally through sales of capital stock, borrowings and cash from operations. We expect to incur increasing expenses over the next several years, principally to develop and commercialize our ePlex system and additional diagnostic tests, as well as to further increase our manufacturing capabilities and domestic and international commercial organization.

## Table of Contents

### Our Products and Technology

We have a menu of eight tests for use with our XT-8 instrument. Four diagnostic tests which run on our XT-8 instrument have received FDA clearance: our Respiratory Viral Panel; our Cystic Fibrosis Genotyping Test; our Warfarin Sensitivity Test; and our Thrombophilia Risk Test. We have also developed a number of hepatitis C virus, or HCV, genotyping tests and custom manufactured reagents, as well as other research-based and pharmacogenomics products, versions of which are available for use with our XT-8 instrument for research use only (RUO).

In addition, we have developed our sample-to-answer ePlex instrument, which integrates automated nucleic acid extraction and amplification with our eSensor detection technology to enable operators using ePlex to place a raw or a minimally prepared patient sample directly into our test cartridge and obtain results without any additional steps. This sample-to-answer capability is enabled by the robust nature of our eSensor detection technology, which is not impaired by sample impurities that we believe hinder competing technologies. We have designed our ePlex system to further simplify workflow and provide powerful, cost-effective molecular diagnostics solutions to a significantly expanded group of hospitals and reference laboratories. We have initiated development programs for seven assays for our ePlex instrument, which include: a respiratory panel (RP); gram-positive (GP), gram-negative (GN), and fungal pathogen (FP) blood culture identification panels; a gastrointestinal (GI) pathogen panel; an HCV genotyping test (HCVg); and a central nervous system (CNS) panel. We intend to continue investing in our ePlex system and its related test menu for the foreseeable future.

### Revenue

Revenue from operations includes product sales, principally of our diagnostic tests for use with our XT-8 system. We primarily place our XT-instrument with customers through a reagent rental agreement, under which we retain title to the instrument and customers commit to purchasing minimum quantities of reagents and test cartridges over a period of one to three years. We also offer our XT-8 instrument for sale.

Revenue also includes licensing revenue from the out-licensing of our electrochemical detection technology. We may enter into additional sub-licenses of our technology generating additional revenue, but do not anticipate that this will provide a significant portion of our future revenue.

### Cost of Revenues

Cost of revenues includes the cost of materials, direct labor and manufacturing overhead costs used in the manufacture of our consumable test kits for our XT-8 system, including royalties on product sales. Cost of revenues also includes depreciation on revenue generating instruments that have been placed with our customers under a reagent rental agreement, cost of instruments sold to customers, amortization of licenses related to our products and other costs such as warranty, royalty and customer and product technical support. We manufacture our test cartridges in our facility and have recently invested in significant capacity for expansion. This potential underutilized capacity may result in a high cost of revenues relative to revenue, if manufacturing volumes are not able to fully absorb operating costs. Our XT-8 instruments are procured from a contract manufacturer and are generally capitalized as fixed assets and depreciated on a straight-line basis over their useful life as a charge to cost of revenues. We expect our cost of revenues to increase as we place additional XT-8 instruments and manufacture and sell additional diagnostic tests; however, we expect our gross margins related to our XT-8 products to increase as manufacturing efficiencies, improved procurement practices, instrument reliability increases and other improvements decrease costs as a percentage of sales.

### Sales and Marketing Expenses

Sales and marketing expenses include costs associated with our direct sales force, sales management, marketing, technical support and business development activities. These expenses primarily consist of salaries, commissions, benefits, stock-based compensation, travel, advertising, promotions, product samples and trade show expenses. We

expect sales and marketing expenses to increase as we scale-up our domestic and international commercial efforts to expand our customer base.

#### Research and Development Expenses

Research and development expenses primarily include costs associated with the development of our ePlex instrument and its test menu. These expenses also include certain clinical study expenses incurred in preparation for FDA clearance for these products, intellectual property prosecution and maintenance costs, and quality assurance expenses. The expenses primarily consist of salaries, benefits, stock-based compensation, outside design and consulting services, laboratory supplies, contract research organization expenses, clinical study supplies and facility costs. We expense all research and development costs in the periods in which they are incurred.

Table of Contents

General and Administrative Expenses

Our general and administrative expenses include costs associated with our executive, accounting and finance, compliance, information technology, legal, facilities, human resource, administrative and investor relations activities. These expenses consist primarily of salaries, benefits, stock-based compensation costs, independent auditor costs, legal fees, consultants, travel, insurance, and public company expenses, such as stock transfer agent fees and listing fees for NASDAQ.

Foreign Exchange Gains and Losses

Transactions in currencies other than our functional currency are translated at the prevailing rates on the dates of the applicable transaction. Foreign exchange gains and losses arise from differences in exchange rates during the period between the date a transaction denominated in a foreign currency is consummated and the date on which it is settled or translated.

Interest Income and Interest Expense

Interest income includes interest earned on our cash and cash equivalents and investments. Interest expense represents interest incurred on our loan payable and on other liabilities.

Provision for Income Taxes

We make certain estimates and judgments in determining income tax expense for financial statement purposes. These estimates and judgments occur in the calculation of certain tax assets and liabilities, which arise from differences in the timing of recognition of revenue and expense for tax and financial statement purposes.

We assess the likelihood that we will be able to recover our deferred tax assets. We consider all available evidence, both positive and negative, including historical levels of income, expectations and risks associated with estimates of future taxable income, and ongoing prudent and feasible tax planning strategies in assessing the need for the valuation allowance. If it is more likely than not that we will not recover our deferred tax assets, we will increase our provision for income taxes by recording a valuation allowance against the deferred tax assets that we estimate will not ultimately be recoverable.

Our income tax returns are based on calculations and assumptions that are subject to examination by the Internal Revenue Service and other tax authorities. In addition, the calculation of our tax liabilities involves dealing with uncertainties in the application of complex tax regulations. We recognize liabilities for uncertain tax positions based on a two-step process. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates that it is more likely than not that the position will be sustained on audit, including resolution of related appeals or litigation processes, if any. The second step is to measure the tax benefit as the largest amount that is more than 50% likely of being realized upon settlement. While we believe we have appropriate support for the positions taken on our tax returns, we regularly assess the potential outcomes of examinations by tax authorities in determining the adequacy of our provision for income taxes. We continually assess the likelihood and amount of potential adjustments and adjust the income tax provision, income taxes payable and deferred taxes in the period in which the facts that give rise to a revision become known.

Results of Operations — Three months ended March 31, 2016 compared to the three months ended March 31, 2015:

Three Months Ended March 31,				
2016	2015	\$ Change	% Change	
(dollars in thousands)				
Revenue	\$11,064	\$10,107	\$ 957	9 %

Edgar Filing: GenMark Diagnostics, Inc. - Form 10-Q

Our revenue consists primarily of revenue from the sale of test cartridges (which we refer to as consumables), with the remaining portion resulting from the sale of instruments and other revenues.

The increase in revenue for the three months ended March 31, 2016 was due to higher consumables revenues of \$10,770,000 compared to \$9,800,000 for the same period of the prior year. This increase in consumables revenue was primarily driven by an increased volume of infectious disease assay sales. Pricing changes did not have an impact on revenue during the current quarter.

Three Months Ended March 31,  
2016 2015 \$ Change % Change  
(dollars in  
thousands)

Cost of Revenue	\$4,375	\$3,991	\$ 384	10	%
Gross Profit	\$6,689	\$6,116	\$ 573	9	%

The increase in cost of revenue for the three months ended March 31, 2016, compared to the same period of the prior year, was primarily related to the increase in consumables revenue in the current period. Increases in our cost of revenue were attributable to

Table of Contents

product costs of \$209,000 corresponding to volume increases, lower overhead absorption efficiencies of \$417,000, and the expansion of our customer technical support group of \$70,000, partially offset by decreased inventory reserve expense of \$327,000.

Three Months Ended March 31,  
2016 2015 \$ Change % Change  
(dollars in  
thousands)

Sales and Marketing \$3,709 \$3,693 \$ 16 -%

Sales and marketing expenses are primarily comprised of employee-related expenses for our domestic and international commercial organization, and marketing communication and trade show expenses. Sales and marketing expense for the three months ended March 31, 2016 remained consistent as compared to the same period of the prior year.

Three Months Ended March 31,  
2016 2015 \$ Change % Change  
(dollars in  
thousands)

General and Administrative \$3,419 \$3,671 \$ (252 ) (7 )%

The decrease in general and administrative expense for the three months ended March 31, 2016, compared to the same period of the prior year, was primarily driven by a decrease in medical device tax expense of \$138,000 as a result of the suspension of the excise tax, and a \$116,000 decrease in legal expenses.

Three Months Ended March 31,  
2016 2015 \$ Change % Change  
(dollars in  
thousands)

Research and Development \$12,269 \$8,779 \$ 3,490 40 %

The increase in research and development expense for the three months ended March 31, 2016, compared to the same period of the prior year, was primarily driven by an increase in supplies and prototype materials utilized by our assay development teams of \$3,726,000 and increased clinical trials and quality assurance expenses of \$393,000, partially offset by decreased ePlex instrument expenses of \$527,000.

Three Months Ended March 31,  
2016 2015 \$ Change % Change  
(dollars in  
thousands)

Other Income (Expense) \$(215) \$180 \$ (395 ) (219 )%

Other income (expense) represents non-operating income and expense, including, but not limited to, earnings on cash, cash equivalents, restricted cash, marketable securities, and interest expense related to debt.

The change in other income (expense) for the three months ended March 31, 2016, compared to the same period of the prior year, was primarily due to the absence of one-time income of \$223,000 received in 2015 from the release of escrowed proceeds related to our sale of preferred stock of Advanced Liquid Logic, Inc., and an increase in interest expense of \$204,000 on amounts due under the LSA.

Three Months Ended March 31,  
2016 2015 \$ Change % Change  
(dollars in  
thousands)

Income tax expense (benefit) \$35 \$22 \$ 13 59 %

Due to net losses incurred, we have only recorded tax provisions related to minimum tax payments in the United States and tax liabilities generated by our foreign subsidiaries.

Liquidity and Capital Resources

To date, we have funded our operations primarily from the sale of our common stock, borrowings and cash from operations. We have incurred net losses from continuing operations each year and have not yet achieved profitability. As of March 31, 2016, we had \$34,959,000 of working capital, including \$37,988,000 in cash, cash equivalents, and marketable securities.

The following table summarizes, for the periods indicated, selected items in our unaudited condensed consolidated statements of cash flows:

	March 31,	
Three months ended (in thousands):	2016	2015
Net cash used in operating activities	\$(6,043)	\$(8,265)
Net cash used in investing activities	(1,766 )	(1,185 )
Net cash provided by financing activities	330	9,517
Effect of exchange rate on cash	7	(9 )
Net increase (decrease) in cash and cash equivalents	\$(7,472)	\$58

#### Cash flows used in operating activities

Net cash used in operating activities decreased \$2,222,000 for the three months ended March 31, 2016 compared to the same period of the prior year. The decrease in cash used in operating activities was primarily due to \$5,303,000 less cash outflow from changes in operating assets and liabilities, partially offset by a \$3,089,000 increase in net loss. The main drivers in the change in operating assets and liabilities included decreases in accounts receivable, an increase in accrued compensation and an increase in accounts payable.

#### Cash flows used in investing activities

Net cash used in investing activities increased by \$581,000 for the three months ended March 31, 2016, compared to the same period of the prior year, primarily due to increased purchases of property and equipment of \$555,000 to support the commercialization of ePlex.

#### Cash flows provided by financing activities

Net cash provided by financing activities decreased by \$9,187,000 for the three months ended March 31, 2016, compared to the same period of the prior year, primarily due to the \$10,000,000 we borrowed in March 2015 under the LSA, which was partially offset by lower debt issuance costs of \$690,000 and an increase in proceeds from the exercise of employee stock options of \$123,000.

We have prepared cash flow forecasts which indicate, based on our current cash resources available, that we will have sufficient resources to fund our business for at least the next 12 months. We expect capital outlays and operating expenditures to increase over the next several years as we grow our customer base and revenues, and expand our research and development, commercialization and manufacturing activities. Factors that could affect our capital requirements, in addition to those previously identified, include, but are not limited to:

- the level of revenues and the rate of our revenue growth;
- change in demand from our customers;
- the level of expenses required to expand our commercial (sales and marketing) activities;
- the level of research and development investment required to develop and commercialize our ePlex system and maintain our XT-8 system;
- our need to acquire or license complementary technologies;
- the costs of filing, prosecuting, defending and enforcing patent claims and other intellectual property rights;
- competing technological and market developments; and
- changes in regulatory policies or laws that affect our operations.

#### Loan and Security Agreement

In January 2015, we entered into the LSA with Solar Capital Partners (as successor-in-interest to General Electric Capital Corporation), and certain other financial institutions party thereto, as lenders, pursuant to which we obtained (a) up to \$35,000,000 in a series of term loans and (b) a revolving loan in the maximum amount of \$5,000,000. Under the terms of the LSA, as amended, we may, subject to certain conditions, borrow:

- \$10,000,000 on or before March 31, 2015, which we borrowed in March 2015;

- an additional \$10,000,000, subject to our satisfaction of regulatory requirements necessary to CE Mark our ePlex system in Europe by a specified date;
- an additional \$15,000,000, subject to our satisfaction of FDA 510(k) market clearance for the sale of our ePlex system in the United States by a specified date; and

- up to \$5,000,000 in the form of a revolving loan, which is subject to a defined borrowing base as set forth in the LSA. Pursuant to the terms of the LSA, the lenders are granted a security interest in (a) all of our personal property, other than intellectual property (which is subject to a negative pledge), but including our rights to payment in respect of intellectual property, (b) the stock of all of our domestic subsidiaries, and (c) 65% of the voting stock and 100% of the non-voting stock of each of our non-U.S. subsidiaries.

On September 30, 2015 we entered into a first amendment to the LSA, pursuant to which the lenders internally reallocated certain funding commitments under the LSA between the lenders (but did not increase or reduce the aggregate amount of such commitments), and the parties adjusted certain of our administrative financial reporting obligations and the dates by which certain future funding requirements must be satisfied. On March 18, 2016, we entered into a second amendment to the LSA, pursuant to which the parties adjusted the date by which we must satisfy the funding requirements in respect of Term Loan B.

The LSA contains customary affirmative and negative covenants, including, without limitation, delivering reports and notices relating to our financial condition and certain regulatory events and intellectual property matters, as well as limiting the creation of liens, the incurrence of indebtedness, and the making of certain investments, payments and acquisitions, other than as specifically permitted by the LSA.

#### Letter of Credit

In September 2012, we provided a \$758,000 letter of credit issued by Banc of California to the landlord of our executive office facility in Carlsbad, California. This letter of credit was secured with \$758,000 of restricted cash at March 31, 2016.

If we require additional capital, we cannot be certain that it will be available when needed or that our actual cash requirements will not be greater than anticipated. If we raise additional funds through the issuance of equity or convertible debt securities, the percentage ownership of our stockholders could be significantly diluted, and these newly issued securities may have rights, preferences or privileges senior to those of existing stockholders. If we raise additional funds through collaborations and licensing arrangements, we might be required to relinquish significant rights to our technologies or products, or grant licenses on terms that are not favorable to us.

#### Contractual Obligations

Our contractual obligations as of December 31, 2015 are summarized in our Annual Report on Form 10-K for the year ended December 31, 2015.

#### Critical Accounting Policies and Estimates

Our discussion and analysis of our financial condition and results of operations are based upon our unaudited condensed consolidated financial statements, which have been prepared in accordance with U.S. GAAP. The preparation of these financial statements requires us to make certain estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses. We evaluate our estimates on an ongoing basis, including those related to doubtful accounts, inventories, valuation of intangible assets and other long-term assets, income taxes, and stock-based compensation. We base our estimates on historical experience and on various other assumptions we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities not readily apparent from other sources. Actual results may differ from these estimates. Our critical accounting policies and estimates are discussed in our Annual Report on Form 10-K for the fiscal year ended December 31, 2015. There have been no material changes to our critical accounting policies and estimates during the three months ended March 31, 2016.

#### Off-Balance Sheet Arrangements

We have no off-balance sheet arrangements. We have provided a \$758,000 standby letter of credit to our landlord as security for future rent in connection the lease of our executive office facility in Carlsbad, California, which is recorded as restricted cash on our unaudited condensed consolidated balance sheets.

Table of Contents

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

There have been no material changes in our market risks during the quarter ended March 31, 2016. Our exposure to market risk is currently limited to our cash and cash equivalents, all of which have maturities of less than three months, and marketable securities, which have maturities of greater than three months. The goals of our investment policy are preservation of capital, fulfillment of liquidity needs, and fiduciary control of cash and investments. We also seek to maximize income from our investments without assuming significant risk. To achieve our goals, we may in the future maintain a portfolio of cash equivalents and investments in a variety of securities that management believes to be of high credit quality. We currently do not hedge interest rate exposure. Because of the short-term nature of our cash equivalents and investments, we do not believe that an increase in market rates would have a material negative impact on the value of our portfolio.

Interest Rate Risk

As of March 31, 2016, based on current interest rates and total borrowings outstanding, a hypothetical 100 basis point increase or decrease in interest rates would have an immaterial pre-tax impact on our results of operations.

Foreign Currency Exchange Risks

All of our operating facilities are located within the United States. We are a U.S. entity and our functional currency is the U.S. dollar. All of our revenues were derived from sales in the United States. We have business transactions in foreign currencies, however, we believe we have no material exposure to risk from changes in foreign currency exchange rates at this time. We do not currently engage in hedging or similar transactions to reduce our foreign currency risks. We will continue to monitor and evaluate our internal processes relating to foreign currency exchange, including the potential use of hedging strategies.

ITEM 4. CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

We maintain disclosure controls and procedures designed to provide reasonable assurance that information required to be disclosed in reports we file under the Exchange Act is recorded, processed, summarized and reported within the specified time periods and accumulated and communicated to management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure. The design of any system of controls is based, in part, upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Over time, controls may become inadequate because of changes in conditions, or the degree of compliance with policies or procedures may deteriorate. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.

As of the end of the period covered by this report, we carried out an evaluation, under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, of the effectiveness of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act. Based on this evaluation, our Chief Executive Officer and Chief Financial Officer, with the participation of management, concluded that, as of March 31, 2016, our disclosure controls and procedures were effective.

Changes in Internal Control over Financial Reporting

There has been no change in our internal controls over financial reporting that occurred in the quarterly period covered by this report that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.



Table of Contents

PART II. OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

We are from time to time subject to various claims and legal actions in the ordinary course of our business. We believe that there are currently no legal actions that would reasonably be expected to have a material adverse effect on our results of operations or financial condition.

ITEM 1A. RISK FACTORS

There have been no material changes to our risk factors during the three months ended March 31, 2016. For additional information regarding risk factors, refer to Part I, Item 1A, "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2015.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

None.

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

None.

ITEM 4. MINE SAFETY DISCLOSURES

None.

ITEM 5. OTHER INFORMATION

None.

ITEM 6. EXHIBITS

The exhibits listed in the Exhibit Index are incorporated herein by reference.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

GENMARK DIAGNOSTICS, INC.

Date: May 3, 2016 By: /s/ HANY MASSARANY

Hany Massarany  
President and Chief Executive Officer  
(Principal Executive Officer)

Date: May 3, 2016 By: /s/ SCOTT MENDEL

Scott Mendel  
Chief Financial Officer  
(Principal Financial and Accounting Officer)

Table of Contents

EXHIBIT INDEX

Listed and indexed below are all Exhibits filed as part of this report.

Exhibit	Description
3.1	Certificate of Incorporation (incorporated by reference to our Registration Statement on Form S-1 (File No. 333-165562) filed with the Commission on March 19, 2010).
3.2	Amended and Restated Bylaws (incorporated by reference to our Current Report on Form 8-K filed with the SEC on October 31, 2014).
10.1	Second Amendment to Loan and Security Agreement dated March 17, 2016 by and among GenMark Diagnostics, Inc., as borrower, Healthcare Financial Solutions, LLC, as agent and lender, and the lenders signatory thereto.*
10.2	Amendment Number One to Development Collaboration and License Agreement, effective as of January 18, 2016, by and among Clinical Micro Sensors, Inc. d.b.a. GenMark Diagnostics, Inc., Advanced Liquid Logic, Inc., and Illumina, Inc.*
10.3	The GenMark Diagnostics Inc. 2016 Bonus Plan (incorporated by reference to our Current Report on Form 8-K filed with the SEC on February 24, 2016).†
31.1	Certification of Principal Executive Officer Required Under Rule 13a-14(a) and 15d-14(a) of the Securities Exchange Act of 1934, as amended.
31.2	Certification of Principal Financial Officer Required Under Rule 13a-14(a) and 15d-14(a) of the Securities Exchange Act of 1934, as amended.
32.1	Certification of Principal Executive Officer and Principal Financial Officer Required Under Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended, and 18 U.S.C. §1350.
101.INS	XBRL Instance Document.
101.SCH	XBRL Taxonomy Extension Schema Document.
101.CAL	XBRL Taxonomy Extension Calculation Linkbase Document.
101.DEF	XBRL Taxonomy Extension Definition Linkbase Document.
101.LAB	XBRL Taxonomy Extension Label Linkbase Document.
101.PRE	XBRL Taxonomy Extension Presentation Linkbase Document.

† Management compensation plan.

\* GenMark has requested confidential treatment with respect to certain portions of this exhibit.